Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Average PT from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned a consensus recommendation of “Hold” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $9.29.

Several research analysts recently issued reports on the stock. HC Wainwright cut their price target on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Bank of America reissued an “underperform” rating and set a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. William Blair lowered shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Stifel Nicolaus lowered shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, May 13th.

Neumora Therapeutics Stock Up 25.9%

NASDAQ NMRA opened at $1.02 on Friday. The stock has a market capitalization of $164.98 million, a P/E ratio of -0.55 and a beta of 2.73. Neumora Therapeutics has a 52-week low of $0.61 and a 52-week high of $17.19. The firm has a 50-day moving average price of $0.72 and a 200 day moving average price of $3.17.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, equities research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $64,000. Quantbot Technologies LP acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $92,000. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $117,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $135,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.